MedTrace Logo

Delayed Start to Ovarian Stimulation

NCT01614067 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-06-15

Study results available
· View outcomes & findings →

Summary

In couples with infertility secondary to Diminished Ovarian Reserve, the investigators hypothesize that a delayed start (7 day) to ovarian stimulation with an GnRH antagonist (Ganirelix) will improve oocyte maturation and quality, and improve pregnancy outcomes.

Conditions

  • Diminished Ovarian Reserve
  • Infertility
  • In Vitro Fertilization

Interventions

DRUG

Ganirelix acetate

Subjects will receive 7 days of pre-treatment with the GnRH antagonist

Sponsors & Collaborators

Principal Investigators

  • Mitchell Rosen, MD · UCSF Center for Reproductive Health and Fertility Preservation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-07-31
Completion
2014-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01614067 on ClinicalTrials.gov